Please select the option that best describes you:

How do you modify therapy for patients with severe intolerance to imatinib in the adjuvant setting for GIST?  

Do you switch to alternative TKI? Dose reduce?



Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more